Galera Therapeutics, Inc. financial data

Symbol
GRTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
45 Liberty Blvd., Suite 230, Malvern, Pennsylvania
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 331 % -15.4%
Debt-to-equity -126 % +19%
Return On Equity 36.1 % -45.8%
Return On Assets -139 % -16%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.4 M shares +27%
Common Stock, Shares, Outstanding 54.4 M shares +26.8%
Entity Public Float 130 M USD +303%
Common Stock, Value, Issued 54 K USD +25.6%
Weighted Average Number of Shares Outstanding, Basic 54.4 M shares +54.5%
Weighted Average Number of Shares Outstanding, Diluted 54.4 M shares +54.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 18.3 M USD -39.3%
General and Administrative Expense 19.3 M USD -11.3%
Operating Income (Loss) -40 M USD +23.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -59.1 M USD +5.15%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -45.8 M USD +29.1%
Earnings Per Share, Basic -0.08 USD/shares +84%
Earnings Per Share, Diluted -0.08 USD/shares +84%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.5 M USD -47.6%
Assets, Current 15.2 M USD -72%
Property, Plant and Equipment, Net 62 K USD -85.2%
Operating Lease, Right-of-Use Asset 1.17 M USD
Goodwill 881 K USD 0%
Other Assets, Noncurrent 90 K USD -95.3%
Assets 19.7 M USD -67.1%
Accounts Payable, Current 1.05 M USD -82.4%
Accrued Liabilities, Current 831 K USD -88.7%
Liabilities, Current 2.01 M USD -84.8%
Operating Lease, Liability, Noncurrent 1.08 M USD
Liabilities 154 M USD -1.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -442 M USD -11.6%
Stockholders' Equity Attributable to Parent -135 M USD -38%
Liabilities and Equity 19.7 M USD -67.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.79 M USD +58.9%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 200 M shares 0%
Common Stock, Shares, Issued 54.4 M shares +26.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.79 M USD -122%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13.5 M USD -47.7%
Deferred Tax Assets, Valuation Allowance 72.9 M USD +24.7%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 73.7 M USD +24.5%
Operating Lease, Liability 1.21 M USD
Payments to Acquire Property, Plant, and Equipment 59 K USD +136%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -45.8 M USD +28.9%
Lessee, Operating Lease, Liability, to be Paid 1.44 M USD
Property, Plant and Equipment, Gross 530 K USD -71.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 220 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 217 K USD
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 224 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 224 K USD
Deferred Tax Assets, Operating Loss Carryforwards 49 M USD +17.4%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) 0 USD
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 10 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 633 K USD
Operating Lease, Payments 53 K USD +20.5%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 0 USD
Current Federal Tax Expense (Benefit) 0 USD
Depreciation, Depletion and Amortization 9 K USD -55%
Deferred Tax Assets, Net of Valuation Allowance 804 K USD +10.6%
Share-based Payment Arrangement, Expense 4.98 M USD -26.5%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Interest Expense 7.19 M USD -46.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%